Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607303 · ClinicalTrials.gov registry record
Effect of Hormones on Frequency of Headache and Brain Structure and Function in Puberty
A clinical trial of Headache and Gender Identity, sponsored by University of Colorado, Denver.
- Active
- Registry status
- 140
- Enrollment target
- 1
- Study location
NCT05607303: Active study of Headache and Gender Identity, sponsored by University of Colorado, Denver.
NCT05607303 is a study of Headache and Gender Identity that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 140 participants, roughly in line with the 152-participant average among 35 other Headache trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05607303, a study of Headache and Gender Identity, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
With a rising population of transgender adults and youth, there is a need for more research to meet the needs of this community. Transfemale (MTF) youth (male sex, female gender identity) who begin clinical Gender Affirming Hormone Therapy (GAHT) with estrogen may be at a higher risk for headache since estrogen has been linked to headache in cisgender females (female sex, female gender identity). This research hopes to learn more about headache in MTF youth.
Primary Outcome
Measured by headache count from daily headache diary.
Conditions Studied
Interventions
- OTHER Clinical estrogen therapy
Study Locations (1)
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2026-06-30 |
What the registry record for NCT05607303 still lists
NCT05607303 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 152-participant average among 35 other Headache trials with a reported enrollment target.
The record links to 2 conditions, with Headache appearing as the primary indexed condition, and to 1 intervention - of which Clinical estrogen therapy is the first listed.
NCT05607303 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05607303 about?
NCT05607303 is a clinical study titled "Effect of Hormones on Frequency of Headache and Brain Structure and Function in Puberty". With a rising population of transgender adults and youth, there is a need for more research to meet the needs of this community. Transfemale (MTF) youth (male sex, female gender identity) who begin clinical Gender Affirming Hormone Therapy (GAHT) with estrogen may be at a higher risk for headache si...
What is the current status of trial NCT05607303?
This trial is currently active not recruiting. The enrollment target is 140 participants. The study started on 2021-12-14. Estimated completion is 2026-06-30.
What conditions does trial NCT05607303 study?
This clinical trial studies the following conditions: Headache, Gender Identity.
What interventions are being tested in trial NCT05607303?
The interventions under investigation include: Clinical estrogen therapy (OTHER).
Who is sponsoring clinical trial NCT05607303?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607303 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Headache
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05607303's enrollment target sits among peer trials
140 11th of 35 higher than 25 of 35 other Headache trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Headache trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Concussion Recovery and Support Program
RECRUITING · NA
-
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
RECRUITING · Phase 2
-
Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches
RECRUITING
-
Puberty, Testosterone, and Brain Development
RECRUITING
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI